• 1. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 2. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 3. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 4. An apparatus for determining small amounts of alchohol in sour milk and urine
  Analyst, 1964,89, 272-275
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroid esters

Introduction to 9,11-Anhydro Fusidic Acid (CAS No: 74048-41-2) and Its Significance in Modern Medicinal Chemistry

9,11-Anhydro Fusidic Acid, identified by the chemical compound code CAS No: 74048-41-2, represents a cornerstone in the realm of synthetic and medicinal chemistry. This compound, derived from the natural fermentation product fusidic acid, has garnered significant attention due to its unique structural framework and remarkable biological activities. The anhydro modification at the 9 and 11 positions introduces a distinct chemical profile, enhancing its pharmacological potential while maintaining a high degree of specificity in targeting bacterial infections.

The significance of 9,11-Anhydro Fusidic Acid extends beyond its conventional role as an antibiotic precursor. Recent advancements in chemical biology have highlighted its utility as a key intermediate in the synthesis of novel antimicrobial agents. The modified structure not only imparts enhanced stability but also facilitates further derivatization, enabling the development of next-generation therapeutics capable of overcoming emerging antibiotic resistance mechanisms.

In the context of modern pharmaceutical research, 9,11-Anhydro Fusidic Acid has been integrated into innovative drug design strategies. Its molecular scaffold serves as a versatile platform for generating compounds with improved pharmacokinetic properties and reduced side effects. This adaptability is particularly crucial in addressing the growing global challenge of antibiotic-resistant pathogens, where traditional antibiotics are becoming increasingly ineffective.

The synthesis of 9,11-Anhydro Fusidic Acid involves intricate chemical methodologies that underscore its complexity and value. Researchers have developed sophisticated synthetic routes that optimize yield and purity while minimizing environmental impact. These advancements align with the broader industry trend toward sustainable chemistry, ensuring that the production of this vital compound remains both efficient and ecologically responsible.

Recent clinical studies have demonstrated the promising potential of derivatives of 9,11-Anhydro Fusidic Acid in treating difficult-to-treat infections. By leveraging its unique structural features, scientists have engineered analogs that exhibit potent activity against a range of Gram-positive bacteria, including those resistant to conventional antibiotics. Such findings underscore the enduring relevance of this compound in addressing critical healthcare challenges.

The role of CAS No: 74048-41-2 in academic research cannot be overstated. It serves as a fundamental reference point for students and researchers alike, illustrating the principles of stereochemistry, heterocyclic chemistry, and bioorganic synthesis. Its study provides insights into how subtle modifications can significantly alter biological activity, a principle that is pivotal in drug discovery and development.

Looking ahead, the future applications of 9,11-Anhydro Fusidic Acid are poised to expand further. Emerging fields such as nanomedicine and targeted drug delivery systems are exploring its integration into advanced therapeutic modalities. These innovations hold the promise of delivering antibiotics more precisely to infection sites, thereby reducing systemic side effects and improving patient outcomes.

The global pharmaceutical landscape continues to evolve, with an increasing emphasis on personalized medicine and precision therapeutics. Within this framework, 9,11-Anhydro Fusidic Acid stands out as a compound with multifaceted potential. Its ability to serve as both a scaffold for drug development and a reference compound for academic research makes it an indispensable asset in the ongoing battle against bacterial infections.

• 546-43-0(Alantolactone)
• 79233-15-1(Deoxyandrographolide)
• 6990-06-3(Fusidic acid)
• 470-17-7(Isoalantolactone)
• 16711-91-4(11-Keto Fusidic Acid)
• 136040-43-2(Schisanlactone E)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)